Entry level $ 4.62 - Target price $ 5.23 = Stop loss $ 4.40
Alert set for break above $4.50 for possible long entry dependant on volume.
10% short interest will help fuel the rally.
Covered by 4 analysts with a average price target of $13.50 | Buy rating
Company profile
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.
Alert set for break above $4.50 for possible long entry dependant on volume.
10% short interest will help fuel the rally.
Covered by 4 analysts with a average price target of $13.50 | Buy rating
Company profile
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.